-
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/09/09 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced that it has agreed with GlaxoSmithKline (GSK) to terminate their collaboration and license agreement, effective February 28, 2010. Full Article at Freshnews.com
-
WORCESTER The Hanover Insurance Group Inc. has boosted the size of its existing stock buyback program by $100 million, giving the company up to $300 million to purchase Hanover shares on the open market or in other transactions. Full Article at Worcester Telegram & Gazette
-
Pure-play global biologics firms have long pleaded with the government for a tighter regulatory framework for approval of biosimilars in India. Full Article at DNA India
-
-- The state of tomorrow's workforce: over the next five years 40-50% of the U.S. workforce will retire. Full Article at Freshnews.com
-
Hilary Kramer, chief market strategist at A&G Capital Research, is an advisor to institutional and high-net-worth investors. Full Article at Forbes
-
-- Former House Majority Leader Richard Gephardt, Chairman, Council for American Medical Innovation -- Patrick Kennedy (D-RI), United States Congress -- Leonard Bell, Ph.D. , CEO, Alexion Pharmaceuticals, Inc. Full Article at Freshnews.com
-
David Gardner called it. He’s up 1,334%! See what David’s recommending that you buy NEXT. Full Article at Motley Fool
-
Faced with the prospect of losing billions of dollars to generic competitors, Pfizer is laying the foundation for an ambitious leap into the biosimilar business. Full Article at FiercePharma
-
Epizyme 12/9/2009 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. , a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation... Full Article at Biospace
-
It’s a team highly reminiscent of the squads that took him to seven Tour de France wins, funded by an American sponsor lured into the sport by the draw of his star power — yet Lance Armstrong said Tuesday that his new RadioShack ProTour team isn’t... Full Article at VeloNews
